Xeris Biopharma Holdings, Inc.

Health Care
Biotechnology: Pharmaceutical Preparations
www.xerispharma.com

Market Cap $535.68M
Debt $263.83M
Cash $63.36M
EV $736.16M
FCF $NaN

Earnings

loading chart...

Sales & Net Margins

loading chart...

Earnings	-$63.11M
EBIT	-$41.93M
ROA	-13%
Equity	-$28.32M
Growth Stability	1
PE	-8.49
PB	-18.91
P/S	2.86
Price/Cash	0.12
Debt/Equity	-9.32
Net Margins	-35%
Gross Margins	81%
Op. Margins	-22%
Sales Growth YoY	12%
Sales Growth QoQ	13%
Sales CAGR	56%
Equity CAGR	-3%
Earnings Growth YoY	29%
Earnings Growth QoQ	5%

Sales CAGR 5Y	56%
Equity CAGR 5Y	-3%
Earnings CAGR 3Y	59%
Sales CAGR 3Y	59%
Equity CAGR 3Y	-22%
Market Cap	$535.68M
Revenue	$187.36M
Assets	$321.10M
Total Debt	$263.83M
Cash	$63.36M
Shares Outstanding	145.96M
EV	736.16M
Working Capital	71.79M
Current Ratio	1.79
Gross Profit	$152.44M
Shares Growth 3y	5%
Equity Growth QoQ	47%
Equity Growth YoY	-833%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company markets Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

SEC Filings

Direct access to Xeris Biopharma Holdings, Inc. (XERS) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

2024
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2023
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31
2022
- 10-K Dec 31
- 10-Q Sep 30
- 10-Q Jun 30
- 10-Q Mar 31

Sector Comparison

How does Xeris Biopharma Holdings, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Xeris Biopharma Holdings, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

loading chart...

Xeris Biopharma Holdings, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Xeris Biopharma Holdings, Inc..

Years

Calculation mode

	0	1	2	3	4	5	6	7	8	9	10	TV
fcf	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
DCF		$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Value	$0

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Net Margins	-446%	-247%	-86%	-38%	-35%
ROA	-	-38%	-23%	-11%	-13%
ROE	-	-129%	-209%	918%	-

Bad Net Margins (-34.78%)

Net Margins are too low to guarantee profitability in case of higher costs or higher interest rates. Furthermore lower margins cause higher earnings’ volatility.

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years	12/2020	12/2021	12/2022	12/2023	TTM
Debt over FCF	-	-0.91	-	-	-
Debt over Equity	2.58	0.92	4.36	-29.31	-9.32
Growth Stability	-	-	-	-	1

Neutral Debt/FCF ratio (-)

Net Margins are at a level that is not too high nor too low. They are not a competitive advantage but they are not a competitive disadvantage either.

Good Debt/Equity ratio (-9.32)

The company is not overleveraged and has a good balance between equity and debt.

Good Graham’s Stability (1)

The company has a good stability in its earnings, which is a sign of a good competitive advantage.

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years	12/2020	12/2021	12/2022	12/2023	CAGR 5Y
Revenue YoY growth	-	143%	122%	49%	56%
Earnings YoY growth	-	35%	-23%	-34%	-
Equity YoY growth	-	182%	-53%	-115%	-3%
FCF YoY growth	-	19%	-	-	-